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Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common cause of sudden optic
nerve (ON)-related visual loss in persons over the age of 55. The pathogenesis is still unclear and no
effective treatment has been established. The possible pathway is a vicious cycle of ischemia causing
consequential compartment syndrome at the optic nerve head, resulting in further ischemia and optic
nerve ﬁber infarction. Many medical and surgical interventions aim to shorten the duration of disk
edema. The Ischemic Optic Neuropathy Decompression Trial (INODT) was the only level I evidence of
treatment trial but it ended in failure. The use of steroids for acute NAION is still controversial. Several
clinical case-serial reports showed some beneﬁts. A recently developed animal model of anterior
ischemic optic neuropathy may provide valuable preclinical data for both drug testing and treatment
strategies.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
In adults, anterior ischemic optic neuropathy (AION) is the
second most common cause of optic nerve-related visual impair-
ment after glaucoma [1]. AION includes nonarteritic, arteritic and
perioperative types. Non-arteritic anterior ischemic optic neurop-
athy (NAION) is the most common type of AION. The pathogenesis
and treatment of NAION is an interesting and controversial topic.
Implicated causative factors include nocturnal hypotension,
impaired autoregulation of the microvascular supply, vasculopathic
occlusion, and venous insufﬁciency [2]. Although NAION is a dis-
ease of presumable microvascular ischemia at the paraoptic
branches of the short posterior ciliary arteries, there is no throm-
botic evidence or any systemic disorder tightly associated with
NAION except for diabetes mellitus [3,4]. Patients with NAION
clinically present with painless blurry vision associated with pallid
swelling and hemorrhage of the optic disc, resulting in retinal
ganglion cells apoptosis and permanent vision loss [5]. The most
common pattern of visual ﬁeld defect is an altitudinal defect, and
about two thirds of the visual ﬁeld defect is a lower altitudinal
visual ﬁeld defect (Fig. 1).lmology, Buddhist Tzu Chi
ualien, Taiwan. Tel.: þ886 3
ddhist Compassion Relief Tzu ChiAcute disk edema in NAION may contribute to further axonal
damage via a vicious cycle of ischemia causing edema and
compartment syndrome, so medical and surgical interventions aim
to shorten the duration of disk edema to prevent further axonal
ischemia to decrease neuron death [6,7]. However, there is no
generally accepted treatment for NAION. We review and summa-
rize medical and surgical therapies being reported in the literature
based on the level of evidence [8].
2. Assessment of level of evidence
We classiﬁed recent clinical studies of NAION treatment based
on the Oxford Centre for Evidence-Based Medicine - levels of evi-
dence [8] (Table 1). We reviewed all published reports on the
treatment of NAION since 1990. Most associated studies are case
reports, case series and case controlled studies (Level IV and III).
The only class I trial for NAION was the Ischemic Optic Neuropathy
Decompression Trial (IONDT) in 1995 [9] (Table 2).
3. Treatment of acute NAION
3.1. Systemic and local treatment with corticosteroids
The rationale for the use of steroids in NAION comes from the
postulation that steroids decrease capillary permeability, thereby
inducing faster resolution of disk edema. Although there is no
proven treatment for NAION, 10 % of physicians in the USA chooseFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. (A) Fundus photographs of a right eye with optic disc edema during the the active phase of NAION. (B) Normal disc in the left eye of the same patient. (C) Fluorescein fundus
angiogram of the eye with NAION showing a relatively dark part of the disc (ischemic area in the upper half of the disc) and reactive hyperemia with dye leak in the disc (edema area
in the lower half of the disc). (D) Typical inferior altitudinal visual ﬁeld defect correlated with an ischemia lesion in the upper part of the optic disc. (E) Optic coherence tomography
demonstrating that circumpapillary nerve ﬁber layer thickness shows obvious ﬁber thinning in the superior sector and thickening in the inferior sector of the right optic nerve
(solid line) compared with a normal symmetric double hump pattern in the left optic nerve ﬁber layer (dotted line). INF = inferior; NAS = nasal; OD = oculus dexter; OS = oculus
sinister; SUP = superior; TEMP = temporal.
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therapy [10]. A retrospective study by Hayreh and Zimmerman
showed that systemic steroid treatment was effective in patients
with NAION who had an initial visual acuity 20/70 or worse and
were seen within 2 weeks of onset [11]. However, their patients
were not randomized, and the untreated group had more vascular
risk factors, making it hard to interpret whether oral steroids is a
treatment of choice in NAION (Level III) [11e13]. Moreover, a recent
study in ten patients with NAION showed that high-dose systemic
steroid (oral prednisolone 80 mg/day) treatment did not show any
beneﬁcial effects in NAION, and three treated patients even had
complications caused by steroid application [14]. Thesecontroversial results can be explained by a high spontaneous
improvement rate in NAION (41%) and a broad spectrum of clinical
presentations. These variable clinical manifestations of NAION not
only easily bias clinical studies, but cause difﬁculty in designing a
prospective study [9,15]. The rationale for intravitreal injection of
steroids is the same as for systemic steroids. In clinical practice,
intravitreal injection of triamcinolone acetonide (TA, 4 mg) is
routinely used to treat retinal edema in conditions such as diabetic
retinopathy or retinal vascular occlusion [16e18]. However, only
case controlled report [19] (Level III) and case series [20,21] (Level
IV) applied local intravitreal injection of TA in NAION. The results
were inconclusive though some patients had visual improvement
Table 1
Level of evidence and type of study.
Level I: Systematic review of randomized trials (RT) and high quality RT (e.g., > 80% follow up, narrow conﬁdence interval)
Level II: Systematic review of cohort studies, lesser quality RT (e.g., <80% follow up, wide conﬁdence interval, no clear randomization, problems with blinding),
individual cohort study; including matched cohort studies (prospective comparative studies), ecological studies
Level III: Systematic review of case-control studies, individual case-control study
Level IV: Case-series, poor quality cohort and case-control studies
Level V: Expert opinion
This chart is modiﬁed from material published by the Center for Evidence-Based medicine, Oxford, UK. March 2009.
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effects of TA and further concerns about intraocular pressure
elevation after TA injection.
3.2. Intravitreal anti-vascular endothelial growth factor agents
(anti-VEGF)
VEGF is a signal protein that stimulates angiogenesis and in-
creases microvascular permeability. Anti-VEGF agents such as
bevacizumab and ranibizumab inhibit the signaling of VEGF,
thereby potentially decreasing optic disk edema [7]. In recent
clinical applications, anti-VEGF agents were routinely used in age-
related neovascular macular degeneration and in macular edema
associated with other retinal vascular disorders. Prescott et al.
concluded that anti-VEGF therapy has no beneﬁcial effects in
NAION [22]. However, bevacizumab treatment in NAION was
limited to one case report and one case series (Level IV), with only
one patient got visual improvement [22,23]. A case report of
another anti-VEGF agent, ranibizumab, concluded it was effective in
reducing optic nerve swelling but there was no improvement in
visual acuity (Level IV) [24]. Intravitreal anti-VEGF therapy for
NAION requires further research to explore the potential vasocon-
strictor effects and the stress on the cardiovascular system [25]. A
preclinical trial in animal models or a randomized clinical trial may
determine the role of anti-VEGF in NAION.
3.3. Aspirin
Only one study evaluated aspirin use and concluded that aspirin
did not improve the visual outcome of NAION [26]. There was no
beneﬁt from reducing the risk of development of NAION in the
fellow eye after taking aspirin [27]. However, other reports showed
that aspirin reduced the incidence of NAION in a second eye [28,29].
Aspirin treatment failed because NAION is a hypotensive disorder,
not a thromboembolic disorder [15].Table 2
Summary of studies on the treatment of NAION.
Author (Year) Level of
evidence
Type of study Treatment (Dose)
Botelho (1996) [26] III Retrospective case control Aspirin
Johnson (2000) [42] III Retrospective Levodopa (100 mg levo
carbidopa 3 times daily
Wilhelm (2006) [30] II Randomized controlled Brimonidine 0.2%
Modarres (2011) [31] III Prospective cases series Intravitreal injection of
erythropoietin
IONDT (1995) [9] I Randomized controlled Optic nerve sheath deco
Hayreh (2008) [11] III Nonrandomized controlled Oral prednisone (80 mg
Kaderli (2007) [19] III Case control Intravitreal triamcinolo
Jonas (2007) [20] IV Cases series Intravitreal triamcinolo
Bennett (2007) [23] IV 1 total Case report Intravitreal bevacizuma
Prescott (2012) [22] IV Case series Intravitreal bevacizuma
Pece (2010) [24] IV Case series Intravitreal ranibizuma
IONDT ¼ Ischemic Optic Neuropathy Decompression Trial; NAION ¼ nonarteritic anterio3.4. Other neuroprotective agents
Other interesting treatments for NAION in the past decade
involved neuroprotection. Disappointingly, levodopa and carbidopa
failed to provide beneﬁcial effects in NAION. In a prospective,
double-masked, placebo controlled trial, brimonidine tartrate 0.2%
eyedrops showed no therapeutic effects in patients with acute
NAION (Level 1, 36 patients) [30]. Intravitreal injection of erythro-
poietin seemed to be effective (Level IV, 31 cases without control
group). Twenty-seven eyes had visual acuity improvement (87%) at
6 months of follow up but there was no improvement in the visual
ﬁeld [31]. However, this study did not have a control group to
strengthen its signiﬁcance.
3.5. The Ischemic Optic Neuropathy Decompression Trial (IONDT)
In 1989, Sergott et al. reported optic nerve decompression
improved the progressive form of NAION in a case serial report [32].
This report brought on worldwide debate. To resolve this issue, a
multicenter-trial was developed. The Ischemic Optic Neuropathy
Decompression Trial (IONDT), a randomized, single-blind, multi-
center trial assessed the safety and efﬁcacy of optic nerve decom-
pression in cases of acute onset of NAION (Level 1, 258 patients). A
window was made in the optic nerve sheath surrounding the optic
nerve and theoretically releasing the pressure surrounding the optic
nerve to relieve compartment syndrome. The IONDT found that
surgery for NAION was not only ineffective, but could be harmful,
and the trial was stopped early [9]. A database review in 2012 also
indicatednoevidence of a beneﬁcial effect of surgery forNAION [33].
4. Using an animal model of NAION to investigate
pathogenesis and drug efﬁcacy
No effective, standard treatment for NAION has been reported in
the literature. A prospective, randomized clinical trial is difﬁcult toOutcome
No VA or VF improvement
dopa/25 mg
)
VA improvement in 77% treated/30% of untreated
No VA or VF improvement
2000 unit of VA improvement in 61.2% treated, no VF improvement
mpression No difference in VA outcome and more surgical
patients worsened
tapering dose) VA improvement in 69.8% treated/40.5% untreated;
VF improvement in 40.1% treated/24.5% untreated
ne (4 mg) VA improvement in treated group
ne (20 mg) No VA improvement
b (1.25 mg/0.05 mL) VA and disc swelling improve
b (1.25 mg/0.05 mL) No effect on VA and VF
b (0.5 mg/0.05 mL) Reducing optic nerve swelling, no functional improvement
r ischemic optic neuropathy; VA ¼ visual acuity; VF ¼ visual ﬁelds.
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spontaneous visual improvement rate of about 40% without
treatment.
Recently, primate and rodentmodels of AION (rAION) have been
developed and the mechanism of ischemic optic neuropathy has
been studied [34e39]. To create a rAION model, a photodynamic
application using both a photosensitizing agent and laser was
developed [39]. The preferred model involves inducing transient
coagulopathy, and the severity of the ischemic area can be adjusted
by laser. After injection of a photosensitizing agent (Rose bengal
[RB; Sigma-Aldrich (St.Louis, USA)]) through the tail vein, an argon-
green laser light was aimed at the optic disc of the animals. This
procedure creates photothrombosis on the vascular endothelium
with both laser and RB applications. The rAION model is different
than a central retinal vein occlusion (CRVO) model. The unit energy
of a CRVO is higher and the laser time is longer (>25 s) than in the
AION model and the target is the retinal veins near the optic head
[40,41].
The method used to create AION in animal models may be quite
different from the pathogenesis of human NAION [39]. The rAION
model nevertheless provides a platform on which to test several
potential treatments and illustrate the pathogenesis of NAION. The
results of preclinical trials in the rAION model may bring us evi-
dence to translate into new clinical trials for NAION.5. Conclusion
NAION remains pathophysiologically unclear, and possible fac-
tors are vasculopathic occlusion or venous insufﬁciency impairing
the autoregulation of microvascularity around the optic disc.
Controversial treatments remain in the literature. Potential strate-
gies for the future treatment of NAION should aim to avoid
compartment syndrome to decrease secondary damage to axons,
protect retinal ganglion cells from death (anti-apoptosis) and even
use of regenerative medicine such as stem cell therapy.References
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